|
A comprehensive review on vitiligo and its pharmacotherapy: Recent trends and future challenges
Asmaa Moafa1, Fahad Khalawi2, Nagaraja Sreeharsha3
1 Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Asha 31982, Saudi Arabia
2 Postgraduate Student, Collage of Pharmacy, Jazan University, Saudi Arabia
3 Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Asha 31982, Saudi Arabia; Professor, Department of Pharmaceutics, Vidya Siri College of Pharmacy, Bengaluru, Karnataka, India
Correspondence Address:
Asmaa Moafa,
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982
Saudi Arabia
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijmo.ijmo_15_20
|
|
Approximately 1% of population in the world is affected by an intriguing skin depigmentation disorder, vitiligo. Typically, a vitiligo lesions are seen as white milky, nonscaly patches with separate edges. Vitiligo is caused by a selective loss of epidermal melanocytes. In vitiligo, there is impaired melanocyte regeneration and/or multiplication. Although the proportion of the population affected by this disease is very low, the disease is associated with a lot of social stigmas. This defect has an important effect on the life of the patient and still a persistent load.
|
Search Pubmed for